These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 31222577)

  • 1. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
    Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
    Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
    Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
    Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
    Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
    J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
    Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
    Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
    McNeil BK; Sorbellini M; Grubb RL; Apolo A; Cecchi F; Athauda G; Cohen B; Giubellino A; Simpson H; Agarwal PK; Coleman J; Getzenberg RH; Netto GJ; Shih J; Linehan WM; Pinto PA; Bottaro DP
    J Transl Med; 2014 Oct; 12():199. PubMed ID: 25335552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer.
    Chen S; Jiang L; Zheng X; Shao J; Wang T; Zhang E; Gao F; Wang X; Zheng J
    Cancer Sci; 2021 Jul; 112(7):2905-2914. PubMed ID: 33931925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostics of ovarian cancer via metabolite analysis and machine learning.
    Yao JZ; Tsigelny IF; Kesari S; Kouznetsova VL
    Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 37032481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
    Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
    OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
    Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
    Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
    Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
    Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
    Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
    Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
    Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
    PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
    Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
    Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
    Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
    PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovering biomarkers in bladder cancer by metabolomics.
    Zhang WT; Zhang ZW; Guo YD; Wang LS; Mao SY; Zhang JF; Liu MN; Yao XD
    Biomark Med; 2018 Dec; 12(12):1347-1359. PubMed ID: 30507300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
    Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
    Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
    Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
    BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding distinctions between oral cancer and periodontitis using saliva metabolites and machine learning.
    Kouznetsova VL; Li J; Romm E; Tsigelny IF
    Oral Dis; 2021 Apr; 27(3):484-493. PubMed ID: 32762095
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.